Charles Schwab Investment Management Inc. lowered its position in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) by 5.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 499,299 shares of the oil and gas company's stock after selling 30,223 shares during the period. Charles Schwab Investment Management Inc. owned about 1.06% of Core Laboratories worth $8,643,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Eagle Asset Management Inc. acquired a new position in Core Laboratories in the 3rd quarter valued at approximately $3,531,000. Fisher Asset Management LLC increased its holdings in Core Laboratories by 19.5% in the third quarter. Fisher Asset Management LLC now owns 990,267 shares of the oil and gas company's stock valued at $18,350,000 after purchasing an additional 161,278 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Core Laboratories by 19.1% in the third quarter. The Manufacturers Life Insurance Company now owns 21,511 shares of the oil and gas company's stock valued at $399,000 after purchasing an additional 3,457 shares during the period. Quantbot Technologies LP bought a new position in Core Laboratories during the 3rd quarter worth $211,000. Finally, FMR LLC lifted its holdings in Core Laboratories by 182.9% during the 3rd quarter. FMR LLC now owns 17,057 shares of the oil and gas company's stock worth $316,000 after buying an additional 11,028 shares during the period. Institutional investors and hedge funds own 97.81% of the company's stock.
Core Laboratories Trading Up 0.5 %
Core Laboratories stock traded up $0.08 during trading hours on Thursday, reaching $15.47. 456,792 shares of the company's stock were exchanged, compared to its average volume of 340,005. The firm has a market capitalization of $724.41 million, a PE ratio of 23.44, a PEG ratio of 0.99 and a beta of 2.38. The company has a quick ratio of 1.71, a current ratio of 2.32 and a debt-to-equity ratio of 0.49. The firm's 50 day simple moving average is $16.60 and its 200 day simple moving average is $18.12. Core Laboratories Inc. has a twelve month low of $12.95 and a twelve month high of $25.13.
Core Laboratories (NYSE:CLB - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The oil and gas company reported $0.23 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.23. Core Laboratories had a return on equity of 16.24% and a net margin of 5.99%. Research analysts predict that Core Laboratories Inc. will post 0.96 earnings per share for the current year.
Core Laboratories Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Monday, February 10th were paid a $0.01 dividend. The ex-dividend date was Monday, February 10th. This represents a $0.04 annualized dividend and a dividend yield of 0.26%. Core Laboratories's dividend payout ratio is presently 6.06%.
Analysts Set New Price Targets
Separately, Citigroup raised Core Laboratories from a "sell" rating to a "neutral" rating and increased their price target for the company from $15.00 to $16.00 in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $17.50.
Read Our Latest Analysis on Core Laboratories
About Core Laboratories
(
Free Report)
Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.
Further Reading
Before you consider Core Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Core Laboratories wasn't on the list.
While Core Laboratories currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
